Allogene Therapeutics (ALLO)
NASDAQ:ALLO
Want to see ALLO full AI Analyst Report?
Total Valuation
Allogene Therapeutics has a market cap or net worth of $711.02M. The enterprise value is $528.73M.
Market Cap$711.02M
Enterprise Value$528.73M
Share Statistics
Allogene Therapeutics has 345,154,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding345,154,570
Owned by Insiders6.69%
Owned by Institutions23.39%
Financial Efficiency
Allogene Therapeutics’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -52.84%.
Return on Equity (ROE)-0.65
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-52.84%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee0.00
Profits Per Employee-844.63K
Employee Count226
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Allogene Therapeutics is ―. Allogene Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio0.00
PB Ratio1.03
Price to Fair Value1.03
Price to FCF-2.02
Price to Operating Cash Flow-4.53
PEG Ratio0.05
Income Statement
In the last 12 months, Allogene Therapeutics had revenue of 0.00 and earned -190.89M in profits. Earnings per share was -0.87.
Revenue0.00
Gross Profit-12.36M
Operating Income-206.93M
Pretax Income-190.89M
Net Income-190.89M
EBITDA-177.45M
Earnings Per Share (EPS)-0.87
Cash Flow
In the last 12 months, operating cash flow was -109.23M and capital expenditures -296.00K, giving a free cash flow of -109.53M billion.
Operating Cash Flow-109.23M
Free Cash Flow-109.53M
Free Cash Flow per Share-0.32
Dividends & Yields
Allogene Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.72
52-Week Price Change71.67%
50-Day Moving Average2.12
200-Day Moving Average1.78
Relative Strength Index (RSI)51.95
Average Volume (3m)7.60M
Important Dates
Allogene Therapeutics upcoming earnings date is Aug 5, 2026, Before Open (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 5, 2026
Ex-Dividend Date―
Financial Position
Allogene Therapeutics as a current ratio of 7.93, with Debt / Equity ratio of 29.06%
Current Ratio7.93
Quick Ratio7.93
Debt to Market Cap0.00
Net Debt to EBITDA-0.18
Interest Coverage Ratio-192.50
Taxes
In the past 12 months, Allogene Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Allogene Therapeutics EV to EBITDA ratio is -1.88, with an EV/FCF ratio of -2.23.
EV to Sales0.00
EV to EBITDA-1.88
EV to Free Cash Flow-2.23
EV to Operating Cash Flow-2.24
Balance Sheet
Allogene Therapeutics has $266.89M in cash and marketable securities with $81.05M in debt, giving a net cash position of $185.84M billion.
Cash & Marketable Securities$266.89M
Total Debt$81.05M
Net Cash$185.84M
Net Cash Per Share$0.54
Tangible Book Value Per Share$1.33
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Allogene Therapeutics is $8.58, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.58
Price Target Upside259.21% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast37.45%